You are here

Article Text

Article menu
Download PDFPDF
Unexpected outcome (positive or negative) including adverse drug reactions
CASE REPORT
Orbital recurrence of iris melanoma 21 years after enucleation
  1. Emilie Bergeron1,
  2. Nadia Lihimdi1,
  3. Dan Bergeron1,2,
  4. Solange Landreville2,3
  1. 1Centre universitaire d'ophtalmologie, CHU de Quebec-Université Laval, Quebec City, Quebec, Canada
  2. 2Département d'ophtalmologie, Université Laval, Quebec City, Quebec, Canada
  3. 3Centre universitaire d’ophtalmologie-Recherche, CHU de Quebec-Université Laval, Quebec City, Quebec, Canada
  1. Correspondence to Professor Solange Landreville, Solange.Landreville{at}fmed.ulaval.ca

Summary

We present the case of a 56-year-old man who developed a neoplasm of epithelioid histology in his anophthalmic left orbit 21 years after he underwent enucleation for a spindle cell iris melanoma. The recurrent tumour was managed by orbital exenteration. Neither further recurrence nor metastasis was diagnosed over a 5-year follow-up period. This case, along with five other similar cases in the literature,1–3 emphasises the importance of long-term follow-up after treatment of iris melanoma.

  • ophthalmology
  • oncology
  • pathology
  • surgical oncology

https://doi.org/10.1136/bcr-2017-221137

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors EB and NL did the literature search and wrote the report. DB provided clinical care to the patient and reviewed the manuscript. SL provided guidance on histopathological information and edited the figures and manuscript.

    • Funding Supported by the Vision Health Research Network (VHRN) from the Fonds de recherche du Québec – Santé (FRQS) and the Fonds de recherche du Centre universitaire d’ophtalmologie du CHU de Québec. EB is supported by a scholarship from the VHRN. SL is a research scholar from the FRQS.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Ethics approval Obtained. Ethics approval by CHU de Québec-Université Laval.

    • Provenance and peer review Not commissioned; externally peer reviewed.